Targeting the BET family for the treatment of leukemia

Epigenomics. 2014 Apr;6(2):153-5. doi: 10.2217/epi.14.5.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Azepines / therapeutic use
  • Benzodiazepines / therapeutic use
  • Cell Cycle Proteins
  • Cell Proliferation / drug effects
  • Gene Expression / drug effects
  • Humans
  • Leukemia / drug therapy*
  • Leukemia / genetics
  • Nuclear Proteins / antagonists & inhibitors*
  • Nuclear Proteins / genetics
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Quinazolines / therapeutic use
  • Quinazolinones
  • RNA-Binding Proteins / antagonists & inhibitors*
  • Transcription Factors / antagonists & inhibitors*
  • Triazoles / therapeutic use

Substances

  • (+)-JQ1 compound
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • Azepines
  • BRD2 protein, human
  • BRD3 protein, human
  • BRD4 protein, human
  • BRDT protein, human
  • Cell Cycle Proteins
  • Nuclear Proteins
  • Quinazolines
  • Quinazolinones
  • RNA-Binding Proteins
  • Transcription Factors
  • Triazoles
  • Benzodiazepines
  • molibresib
  • apabetalone
  • Protein Serine-Threonine Kinases